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Joshua D. Bowling 
TARGETING THE PROTEIN TYROSINE PHOSPHATASE, SHP2, AND PI3K IN FLT-3 
ITD+ LEUKEMIA 
Internal tandem duplications in the fms-like tyrosine kinase receptor (FLT3-
ITDs) cause constitutive activation of the receptor and confer a poor prognosis in 
acute myeloid leukemia (AML). We hypothesized that Shp2 interacts with FLT3-ITD 
via protein complexes at tyrosine (Y) 768, 955, and/or 969 and that Shp2 and PI3K 
work cooperatively to promote FLT3-ITD-induced leukemogenesis. Consistently, 
mutation of N51-FLT3 tyrosine 768 to phenylalanine reduced proliferation and 
levels of phospho-Erk compared to N51-FLT3-expressing cells while having no 
effect on levels of phospho-STAT5.  In transplants, C3H/HeJ mice injected with 
either WT-FLT3-, N51-FLT3-, or N51-Y768F-expressing cells showed that mutation 
of Y768 had no effect on overall survival. In addition, pharmacologic inhibition of 
Shp2 with II-B08 or PI3K with GDC-0941 in N51-FLT3-expressing cells and primary 
patient samples showed decreased proliferation.  A possible mechanistic 
explanation for reduced proliferation and selective reduction of P-Erk levels in the 
N51-FLT3-Y768-expressing cells is through decreased recruitment of Grb2, which 
participates with son of sevenless, SOS, to activate the RAS-Erk signaling pathway.  
The lack of improvement in overall survival could be due to preserved STAT5 
signaling, as observed during in vitro experiments.  Collectively, these data suggest 
that the tyrosine 768 residue plays an important role in phospho-Erk signaling in 
N51-FLT3-expressing cells, and that pharmacologic therapy with Shp2 or PI3K 
inhibitors may provide a novel treatment approach for FLT3-ITD positive AML.  For 
future directions, we plan to treat mice with the Shp2 inhibitor, II-B08, the PI3K 
inhibitor, GDC-0941, or a combination to determine the effect on overall survival. 
Rebecca Chan, MD, PhD, Chair 
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CHAPTER ONE 
INTRODUCTION 
Acute Myeloid Leukemia 
Acute myeloid leukemia (AML) is a heterogeneous disease characterized by 
clonal proliferation of myeloid precursor cells, with a reduced ability to differentiate 
into mature cells.  It accounts for roughly 25% of all adult leukemias, with the 
American Cancer society estimating that 19,950 people will be diagnosed with AML 
in the US during 2016 (Deschler and Lubbert 2006; ACS 2016).  Although this 
disease affects both the young and the elderly, the majority of patients are over the 
age of 65 (Deschler and Lubbert 2006)(Figure 1.1).  Progress has been made in 
improving survival in younger populations – the 5-year survival in patients aged 15-
24 in England has improved from 7% to 53% during 1971-2006; however, in 
patients aged 60-69 the improvement has been more modest, from 2% to 13% 
during this same time period (Shah 2013)(Figure 1.2).   With an aging population, 
the numbers of affected individuals are projected to increase, creating an urgent 
need for improved treatments and curative therapy for AML.  However, the 
increased age of patients also brings increased medical co-morbidities and reduced 
tolerance of cytotoxic chemotherapy and radiation (Deschler and Lubbert 2006; 
Estey and Dohner 2006; Melchert 2006).  Therefore, novel therapies with reduced 
toxicity are needed to treat patients with AML who would otherwise receive only 
supportive care. 
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Figure 1.1: AML predominately affects those over the age of 60 years. 
Graphical representation of the number of people diagnosed with AML out of 
100,000, adapted from Deschler and Lubbert (2006). 
 
 
 
 
Figure 1.2: Proportion of patients cured of AML by year of diagnosis. 
Graphical representation showing the proportion of patients achieving cure in each 
age group, arranged by year of diagnosis from 1971-2006, adapted from Shah, et al. 
(2013). 
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FLT3-ITD mutations in AML 
Internal tandem duplications in the FMS-like tyrosine kinase (FLT3-ITD) are 
insertions of amino acids near the juxtamembrane domain and are present in 
approximately 25% of all AML patients, conferring a poor prognosis (Nakao, 1996; 
Thiede, 2002; Kottaridis, 2001).  An illustration of WT-FLT3 and several described 
ITD insertions is presented in Figure 1.3 (Choudhary, 2005; Mizuki, 2000; Kelley, 
2002).  The importance of FLT3-ITDs as a poor prognostic factor in AML is 
established, and has been demonstrated by numerous investigators (Abu-Duhier, 
2000; Kottardis, 2001, Schlenk, 2008). The decreased survival of patients with 
FLT3-ITD+ AML compared to FLT3-ITD negative AML is illustrated in Figure 1.4.  
FLT3-ITD mutations result in constitutive FLT3 phosphorylation and FLT3 
ligand (FL) independent hyperproliferation (Mizuki, 2003; Murata, 2003; 
Hayakawa, 2000; Kiyoi, 2002).  FLT3-ITDs also cause a promiscuous activation of 
signal transducer and activator of transcription 5, STAT5, which is known to 
activate anti-apoptotic proteins such as Bcl-XL (Spiekermann, 2003; Hayakawa, 
2000; Choudhary, 2007; Rocnik, 2006).  Previous work in our lab has shown the 
importance of Shp2, a protein tyrosine phosphatase, in contributing to the leukemic 
phenotype in FLT3-ITDs (Nabinger, 2013).  However, with Shp2 inhibition there 
was not a complete correction of the hyperproliferation seen in FLT3-ITDs, which 
has led to this current study. We wish to investigate the role of 
phosphotidylinositol-3-kinase (PI3K) and its cooperative role with Shp2 in FLT3-
ITD-induced leukemia.   
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Figure 1.3: Representative schematic diagram showing duplication in ITDs. 
Schematic diagram of several internal tandem duplications that have been observed 
in AML, including the N51-FLT3 used for the experiments in this project 
(Choudhary, 2005; Mizuki, 2000; Kelley, 2002). EC – extracellular, TM – 
transmembrane, JM-juxtamembrane, TK-1 – kinase domain, TK-2 – kinase domain.  
   
N51 
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Figure 1.4:  Cumulative survival of FLT3-ITD+ vs. FLT3-ITD- patients. 
Kaplan-Meier curve showing cumulative survival of AML patients with or without 
the presence of a FLT3-ITD mutation. Adapted from Abu-Duhier, et al. (2000). 
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Role of the protein tyrosine phosphatase, Shp2, in FLT3-ITD+ AML 
Shp2 is a protein tyrosine phosphatase that is ubiquitously expressed and 
critical for normal hematopoesis (Qu, 1998). Furthermore, there is evidence of gain 
of function Shp2 mutations in hematologic malignancies, as well as overexpression 
of Shp2 in human AML samples (Tartaglia, 2003; Loh, 2004; Bentires-Alj, 2004; Xu, 
2005).  There is also a known interaction of Shp2 with WT-FLT3 at the tyrosine 599 
residue, leading to cellular proliferation through the mitogen activated protein 
kinase (MAPK) pathway (Heiss, 2006).  Given the role of Shp2 in normal 
hematopoetic function, and its presence in hematologic malignancies, the 
hypothesis that it contributes to the leukemic phenotype in FLT3-ITDs was explored 
by previous work in the lab (Nabinger, 2013).  We found that Shp2 was 
constitutively associated with the FLT3-ITD, N51-FLT3, as well as with STAT5.  In 
addition, we found that pharmacologic inhibition of Shp2 with a novel inhibitor, II-
B08, reduced the proliferation of N51-FLT3 expressing cells and primary AML 
samples (Nabinger, 2013).  However, co-immunoprecipitation (Co-IP) showed that 
STAT5 and phospho-STAT5 were still associated with FLT3-ITD following knock-
down of Shp2 (Figure 1.5A), and thymidine incorporation assays revealed reduced, 
but not normalized, levels of cellular proliferation following genetic knockout of 
Shp2 in N51-FLT3-expressing cells (Figure 1.5B).  This finding implies that, while 
Shp2 contributes towards STAT5 activation and cellular hyperproliferation in N51-
FLT3-expressing cells, its loss does not completely normalize the leukemic 
phenotype.  This led to our current study, which examines if the lipid kinase, 
phospho-inositol-3-kinase (PI3K) is playing a role in FLT3-ITD-induced leukemia 
and to what degree it may be having a cooperative effect with Shp2. 
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Figure 1.5: Genetic knock-down of Shp2 does not ablate STAT5 interaction 
with FLT3-ITD, and genetic disruption of Shp2 does not completely normalize 
N51-FLT3-induced proliferation. 
(A) Total cellular proteins from Baf3/N51-FLT3 cells transfected with scrambled 
shRNA (SC) or Shp2-specific shRNA (KD) were immunoprecipitated (IP) 
with anti-FLT3 and immunoblotted (IB) with anti-STAT5, anti-phospho-
STAT5, anti-Shp2, and anti-FLT3.  
(B)  3H-thymidine incorporation assay of transduced, sorted bone marrow low 
density mononuclear cells from Shp2flox/flox;Mx1Cre- and 
Shp2flox/flox;Mx1Cre+ mice in the absence and presence of FL 50 ng/mL; 
two independent experiments combined with n=4 replicates per experiment, 
^p<0.0001 for N51-FLT3 v. WT-FLT at baseline in Cre− cells, ^^p<0.0001 for 
N51-FLT3 v. WT-FLT in response to FL in Cre− cells, *p<0.0001 for N51-
FLT3 in Cre+ cells v. Cre− cells at baseline, and **p<0.0001 for N51-FLT3 in 
Cre+ cells v. Cre− cells in response to FL, statistical analysis performed using 
random effects ANOVA. Adapted from Nabinger, et al. (2013). 
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PI3K in AML 
PI3K comes from a family of lipid kinases that generates second messengers 
which promote proliferation, cellular survival, and migration. Cancer genetics 
studies suggest that the PI3K pathway is the most frequently altered pathway in 
human tumors (Samuels, 2006).  This strong genetic evidence has led to 
considerable interest and effort into the development of small molecule inhibitors 
targeting the PI3K–Akt–mTOR signaling pathway (Fruman, 2014).  Although there 
have been encouraging results using pharmacologic PI3K inhibition in chronic 
lymphoid leukemia (CLL), the mechanism and rationale for targeting PI3K in AML 
has been understudied (Hoellenriegel, 2011). 
Although there is a dearth of studies exploring PI3K inhibition in FLT3-ITD 
positive AML, there is some prior work suggesting a cooperative relationship 
between Shp2, PI3K, and WT-FLT3. Previous investigators have defined that Y768, 
Y955, and Y969 on WT FLT3 recruit the adapter proteins Grb2, Gab2, and the 
regulatory subunit of PI3K, p85, and that mutation of all of these tyrosine (Y) sites 
to phenylalanine (F) results in reduced phospho-Akt levels (Masson, 2009).  As 
shown in figure 1.6, prior work in our lab has also suggested a relationship with 
FLT3-ITDs, as we saw reduced p-Akt levels following administration of II-B08, a 
Shp2 phosphatase inhibitor (Zhang, 2010). Given that Shp2 is reported to 
participate in multi-protein complexes containing Gab2 and p85 in WT FLT3-
expressing cells in response to FL stimulation (Zhang, 1999; Zhang, 2000), we 
hypothesized that Shp2 may cooperate with PI3K by associating with Gab2-
containing complexes at FLT3-ITD Y768, Y955, and/or Y969.  
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Figure 1.6: Inhibition of Shp2 decreases levels of p-Akt in N51-FLT3 cells. 
Immunoblot demonstrating that pharmacologic inhibition of Shp2 with II-B08 leads 
to decreased levels of p-Akt in cells expressing N51-FLT3. 
 
Summary  
AML is a heterogenous disease that has cytogenetic and molecular signatures 
bearing prognostic significance.  One important prognostic marker is the presence 
or absence of FLT3-ITD mutations, which have been shown to confer a poor 
prognosis. In particular, the molecular mechanisms behind FLT3-ITD-induced 
leukemia are not yet fully elucidated. Prior work in the Chan lab has shown a 
positive role for Shp2 in FLT3-ITD-induced hyperproliferation and STAT5 activation 
as well as an increase in survival of mice with genetic knockout of Shp2 (Nabinger, 
2013).  However, the cellular hyperproliferation and aberrant expression of p-
STAT5 was not fully normalized following genetic inhibition of Shp2, suggesting 
alternate or additional pathways promoting FLT3-ITD-induced leukemia. Prior 
work has implicated a signaling relationship between PI3K, Shp2, and WT-FLT3 
(Masson, 2009; Zhang, 1999; Zhang, 2000), and our lab has found a reduction of p-
Akt in N51-FLT3-expressing cells upon pharmacologic inhibition of Shp2. Taken 
together, these findings suggest a potential cooperative relationship between Shp2 
and PI3K in FLT3-ITD positive AML.  Therefore, our current project explored two 
aims: 
FL 100 ng/mL
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Aim 1. We hypothesize that mutation of Y768, Y955, or Y969 will result in 
reduced FLT3-ITD-induced hyperproliferation in vitro and reduced 
myeloproliferative disease in vivo due to reduced PI3K-Akt pathway activation. 
 Aim 2.  We hypothesize that dual pharmacologic inhibition of both Shp2 
phosphatase activity and PI3K activity will work cooperatively to inhibit FLT3-ITD-
induced hyperproliferation in vitro.   
To address the first aim, Y768, Y955, and Y969 were mutated to 
phenylalanine (F), alone and in combination, and constructs were introduced into 
32D cells to determine which tyrosine residue or combination of tyrosine residues 
are most important for FLT3-ITD-induced hyperproliferation.  To address the 
second aim, we tested the anti-proliferative effect of the Shp2 inhibitor, II-B08, and 
PI3K inhibitor, GDC-0941, in FLT3-ITD expressing 32D cells and in primary AML 
patient samples.  
 
Significance 
Given that the majority of AML patients are of advanced age, and cannot 
tolerate the harsh chemotherapy regimens used for standard treatment, they often 
are relegated to supportive care.  Therefore, there is an urgent need to develop less 
toxic therapies to address this growing disease population.  Prior work in the Chan 
lab has elucidated a positive role for Shp2 in FLT3-ITD induced malignant disease.  
However, the leukemic phenotype was not completely normalized following Shp2 
inhibition alone, which led to our hypothesis that there are additional signaling 
molecules or pathways contributing to disease progression.  Our current study 
implicating PI3K in FLT3-ITD induced AML is significant because it will be the first 
study to provide a rationale for PI3K inhibition specifically in FLT3-ITD positive 
AML. Furthermore, given the commercial development and access to PI3K 
inhibitors, the feasibility of moving to clinical trials makes this an area of study 
particularly amenable to translation from the bench to the bedside. 
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CHAPTER TWO 
MATERIALS AND METHODS 
A. Materials 
1. Plasmids 
pMSCV 
pMSCV:  WT-, N51-, and N51-point mutant constructs were expressed using 
the Murine Stem Cell Virus (pMSCV) plasmid. cDNA from human WT-FLT3 or 
patient derived FLT-ITD, N51-FLT3, were sub-cloned in the pMSCV vector co-
expressing green fluorescent protein (EGFP) as a marker.  N51-point mutations 
were generated with site-directed mutagenesis using QuikChange Site-Directed 
Mutagenesis Kit (Stratagene, La Jolla, CA) to yield amino acid changes Y768F, Y955F, 
Y969F, Y768F/Y955F, Y768F/Y969F, Y955F/Y969F, and Y768F/Y955F/Y969F.  
After sequencing the cDNAs to rule out unwanted mutations the flag-tagged FLT3 
point mutants were isolated using BamH1 digestion followed by gel electrophoresis 
and extraction.  The plasmid pMSCV was then cut using Bgl II digestion, followed by 
a phosphatase reaction to prevent the vector from ligating back together.  To move 
the FLT3 insert into pMSCV plasmid, a molar ratio of 1:3 of vector to insert was 
used, along with DNA ligase.  After bacterial transformation, colonies were picked 
and expanded, plasmid DNA was extracted, and an Xho1 restriction enzyme digest 
was performed followed by gel electrophoresis.  The Xho1 digestion was able to 
confirm directionality of the sub-cloned insert since the FLAG-FLT3 cDNA fragment 
had BamH1 sites on both ends and could be ligated into the BglII-digested MSCV 
plasmid in both orientations. Xho1 was chosen since it has an eccentrically located 
restriction site within the FLAG-FLT3 insert, as well as a site on the vector, allowing 
directionality to be confirmed based upon fragment size.  If the orientation was 
correct, bands at 1624 bp and 552 bp would be present, whereas the alternative 
orientation would have bands at 1624 bp and 924 bp. Once correct directionality 
was confirmed, constructs were transfected into nascent 32D cells.  Transfection 
was performed using the Amaxa cell line Nucleofector kit V, with the provided 
protocol.  
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Table 2.1: Oligonucleotide primers used for site-directed mutagenesis. 
Primer Primer Sequence 
Y768F 
Forward CTCTGAAGATGAAATTGAATTTGAAAACCAAAAAAGGCTG 
Reverse 
 
CAGCCTTTTTTGGTTTTCAAATTCAATTTCATCTTCAGAG 
 
Y955F 
Forward CAGAAGAAGCGATGTTTCAGAATGTGGATGG 
Reverse CCATCCACATTCTGAAACATCGCTTCTTCTG 
Y969F 
Forward GAATGTCCTCAGACCTTCCAAAACAGGCGACC 
Reverse GGTCGCCTGTTTTGGAAGGTCTGAGGACATTC 
 
2. Patient Samples 
Patient peripheral blood or bone marrow aspirate samples were obtained at 
the time of diagnostic testing and with prior patient consent.  Approval was 
obtained from Institutional Review Boards of the Indiana University School of 
Medicine.  Using Ficoll-Hypaque, low density mononuclear cells were isolated for in 
vitro proliferation assays. 
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3. Antibodies 
 
Table 2.2: Primary antibodies 
Primary antibodies Company Clone 
T-Akt Cell Signaling N/A 
P-Akt (S473) Cell Signaling 587F11 
P-Erk Cell Signaling N/A 
T-Erk Cell Signaling N/A 
P-Stat5 (Y694) Cell Signaling N/A 
T-Stat5 Cell Signaling 3H7 
T-FLT3 Santa Cruz C-20 
P-FLT3 (Y591) Cell Signaling N/A 
GAPDH Biodesign 
International 
6C5 
 
Table 2.3: Secondary antibodies 
Secondary antibodies Company 
Goat Anti-Rabbit IgG HRP Santa Cruz 
Goat Anti-Mouse IgG HRP Santa Cruz 
 
4. Kits 
Table 2.4: Kits 
Kit Company Catalog 
Number 
Plasmid Maxi-Prep Kit Invitrogen K459501 
Mini-prep Kit Qiagen 27106 
Nucleofector Kit V Amaza/Lonza VCA-1003 
QIA quick gel extraction kit Qiagen 28704 
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5. Mice 
C3H/HeJ 
C3H/HeJ mice were received from Harlan and used for transplant studies. 
 
B. Methods 
1. Cell culture 
32D cells 
32D cells, American Type Culture Collection (ATCC) were cultured in IMDM 
(Invitrogen), 10% FBS (HyClone), 1% Penicillin/streptomycin (Invitrogen), and 10 
ng/ml murine IL-3 (PeproTech). Cells were grown in a humidified incubator at 37oC 
with 5% CO2. Cells were passaged approximately every 2-4 days. 
 
2. Transfection 
32D cells 
Approximately 1.0X106 32D cells were mixed with 1 g each of pMSCV-FLT3 
construct, followed by exposure to an electric current delivered via a Nucleofector 
2b device. 
 
3. Cell Sorting 
Transfected cells were sorted using fluorescence-activated cell sorting 
(FACS) and enhanced green fluorescent protein-expressing (EGFP+) cells were 
cultured for functional and biochemical studies. 
 
4. Thymidine Incorporation Assays 
Cells were starved for 4-6 hours in serum-free IMDM and then plated into 
thymidine incorporation assays either at baseline (no growth factor) or in the 
presence of 100ng/ml FLT3 ligand (FL), with or without inhibitor, and incubated 
overnight at 37oC. The next morning, cells were pulsed with 1Ci tritiated thymidine 
(3H) and incubated for 4-6 hours at 37oC. 3H-Thymidine incorporation was 
determined using an automated 96-well cell harvester (Brandel, Gaithersburg, MD). 
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5. Western blots 
Sorted, EGFP+ cells were collected and protein extracts were prepared as 
previously described (Shi, 2000).  Protein extracts were quantified using Bradford 
reagent (Bio-Rad, Hercules, CA) against protein standards, and read using a Spectra-
Max 340 pc microplate reader. Extracts were then electrophoresed and 
transferred to nitrocellulose as previously described (Chan, 2005). All signals were 
detected by enhanced chemiluminescence and p-STAT5 and p-Erk signals were 
quantitated using ImageJ software (National Institutes of Health, Bethesda, MD). 
 
6. Transplants 
2.0x106 32D cells expressing each of the various constructs including: WT-
FLT3, N51-FLT3, and N51-FLT3-Y768F were injected via tail vein into C3H/HeJ mice 
by the In Vivo Therapeutics Core at the Indiana University School of Medicine. 
Transplanted animals were followed for overall survival, and results were analyzed 
using Kaplan Meier method, significance at 0.05 level. 
 
7. Statistical Analysis 
For combined data from modified N51-FLT3 constructs, unpaired, two-tailed, 
Student’s t test was used.  For Western blot quantification using modified N51-FLT3 
constructs, paired or unpaired, two-tailed, Student’s t test was used.   For the 
transplant study, overall survival was analyzed using Kaplan Meier estimation 
where death was the pertinent event. P values were generated using the log-rank 
tests. For effect of II-B08 and GDC-0941 on N51-FLT3 cell and primary human AML 
cell proliferation, unpaired, two-tailed, Student’s t test was used. For all analyses, 
statistical significance was set at 0.05.  
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RESULTS 
 
Generation of FLT3-ITD constructs and FLT3-ITD-expressing 32D cells  
The original N51-FLT3-ITD cDNA was subjected to site-directed mutagenesis 
to generate various tyrosine (Y) to phenylalanine (F) mutants (Figure 2.1).  Nascent 
32D cells were transfected with MSCV-WT-FLT3, N51-FLT3, and the various N51-
FLT3 tyrosine (Y) to phenylalanine (F) constructs. Afterwards, the cells were sorted 
by FACS and enriched for EGFP positivity, until there were sufficient numbers of 
cells to perform assays.  As an initial pilot experiment, the transfected cells were 
evaluated for proliferation using 3H-thymidine incorporation assay, as shown in 
Figure 2.2.  We consistently saw reduced proliferation with the single mutant N51-
FLT3-Y768F with and without FL.  However, for the other single mutants, we 
observed mixed results including only a modest effect of the N51-FLT3-Y955F 
mutant and paradoxically increased proliferation of cells expressing N51-FLT3-
Y969F when cultured in IL3 (data not shown). Collectively, these pilot studies 
suggested that the Y955 or Y969 sites may actually function to recruit inhibitory 
signaling proteins rather than to recruit activating, stimulatory signaling proteins. 
Based upon the established role of Y768 and the reproducibility of proliferation 
reduction observed in the pilot studies, we focused on the role of Y768 in N51-FLT3-
ITD-induced biochemical signaling and development of myeloproliferative 
neoplasm in vivo. 
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Figure 2.1: Schematic diagram showing N51-FLT3 constructs. 
Schematic representation of tyrosine residues that were mutated from tyrosine (Y) 
to phenylalanine (F) alone and in combination. EC – extracellular, TM-
transmembrane, JM-juxtamembrane, TK-1 – kinase domain, TK-2 – kinase domain 
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Figure 2.2: 3H-thymidine incorporation experiment, using all modified N51-
FLT3 constructs. 
Murine 32D cells were transfected with WT-FLT3, N51-FLT3, N51-FLT3-Y768F, 
N51-FLT3-Y955F, N51-FLT3-Y969F, or combinations, sorted by FACS, and subjected 
to 3H-thymidine incorporation assay in the absence and presence of FL 50 ng/mL; 
representative of three independent experiments with similar results, n=4 
replicates per experiment, data normalized to N51-FLT3 proliferation levels. 
*p<0.0001 for 768, 969,768/955, or TM v. N51-FLT3 at baseline and in the presence 
of FL 50 ng/mL, ^p<0.05 for 955, 768/969, or 955/969 v. N51-FLT3 at baseline and 
in the presence of FL 50 ng/mL, statistical analysis using unpaired, two-tailed, 
student’s t test. 
 
Mutation of N51-FLT3 tyrosine (Y) 768 to phenylalanine (F) diminishes FLT3-
ITD-induced hyperproliferation 
Given the promising results we obtained using the N51-FLT3-Y768F mutant 
in reducing proliferation in pilot studies, we focused the remainder of our work on 
that mutant.  In carrying these studies forward, we found a sequence error in the 
original N51-FLT3-ITD-Y768F construct; therefore, the construct was re-generated, 
re-sequenced, and re-evaluated for proliferation (Fig. 2.3).  Again, we once again 
0
0.2
0.4
0.6
0.8
1
1.2
WT N51 768 955 969 768/955 768/969 955/969 TM
3
H
-T
h
ym
id
in
e
 In
co
rp
o
ra
ti
o
n
 (
C
P
M
+/
-S
.D
.)
Baseline
50ng/ml FL
19 
saw reduced proliferation with mutation of tyrosine (Y) 768 to phenylalanine (F) 
(Figure 2.3); however, the levels were not corrected to WT levels, suggesting 
involvement of multiple signaling pathways.  As previous investigators had found 
that the point mutants WT-FLT3-Y768F, WT-FLT3-Y955F, and WT-FLT3-Y969F 
were relevant for PI3K signaling, we wanted to investigate if the N51-FLT3-Y768F 
mutant caused reduced activation of Akt, Erk, and STAT5 (Masson, 2009).   
 
 
Figure 2.3: Mutation of N51-FLT3 tyrosine (Y) 768 to phenylalanine (F) 
diminishes FLT3-ITD-induced hyperproliferation. 
Murine 32D cells were transfected with WT-FLT3, N51-FLT3, or N51-FLT3-Y768F, 
sorted by FACS, and subjected to 3H-thymidine incorporation assay in the absence 
and presence of FL 50 ng/mL.  Proliferation was normalized to average WT FLT3-
expressing cells at baseline within each independent experiment, data compiled 
from four independent experiments, *n=4, p<0.05 comparing N51-FLT3-Y768F to 
N51-FLT3 in the absence or presence of FL, statistics performed by unpaired, two-
tailed student’s t-test. 
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Mutation of N51-FLT3 tyrosine (Y) 768 to phenylalanine (F) normalizes Erk , 
but not Akt or STAT5 activation 
As we observed reduced cellular proliferation with N51-FLT3-Y768F, we 
next examined its functional role with biochemical analysis. In cells expressing N51-
FLT3-Y768F, there were reduced levels of phospho-Erk compared to N51-FLT3 
expressing cells, with no observed effect on levels of phospho-STAT5 (Figure 2.4).  
Also of note, we saw no difference in phospho-Akt levels between WT-FLT3 and 
N51-FLT3 expressing cells, and mutation of Y768 did not reduce Akt activation 
compared to N51-FLT3.   Together, these findings implicate Y768 as being relevant 
for positive regulation of the RAS-Erk signaling pathway in FLT3-ITD positive AML, 
but having minimal or no effect on PI3K-Akt or STAT5 activation. 
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Figure 2.4: Mutation of N51-FLT3 tyrosine (Y) 768 to phenylalanine (F) 
normalizes Erk , but not Akt or STAT5 activation 
(A) Immunoblot analysis of STAT5 phosphorylation, total STAT5, Akt 
phosphorylation, total Akt,  Erk phosphorylation, total Erk, and FLAG-FLT3 
expression in transfected and sorted 32D cells expressing WT-FLT3-, N51-FLT3-, or 
N51-FLT3-Y768F, repeated in 3 – 5 independent experiments. (B) Band intensities 
were quantitated using densitometry. Data were compiled from the experiments 
and demonstrated graphically. Data shown as ± SEM; *n=3, p<0.05 comparing p-
STAT5/t-STAT5 in N51-FLT3- to WT FLT3-expressing cells (paired, two-tailed 
student’s t test) and ^n=5, p<0.01 comparing p-Erk/t-Erk in N51-FLT3-Y768F- to 
N51-FLT3-expressing cells (unpaired, two-tailed student’s t test). 
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Mutation of N51-FLT3 tyrosine (Y) 768 to phenylalanine (F) has no effect on 
Myeloproliferative disease (MPD) in vivo 
Given the reduced cellular proliferation and reduced Erk activation observed 
in vitro, the next step was to determine if mutation of Y768 would alter overall 
survival in an in vivo model.  A syngeneic transplant using C3H/HeJ mice (Figure 
2.5) was performed, and groups were followed for 70 days.  We observed no 
difference in survival between N51-FLT3 mice and N51-FLT3-Y768F mice (Figure 
2.6) suggesting that mutation of this residue alone is not sufficient to affect the 
progression of myeloproliferative disease in vivo.  One possibility is that, in a 
physiologic model, preserved Akt and STAT5 signaling pathways may be sufficient 
to overcome the reduced cellular proliferation and Erk signaling seen during in vitro 
experiments. 
 
 
 
Figure 2.5: Transplant protocol for N51-FLT3 construct survival study. 
Schematic diagram showing transplant design.  C3H/HeJ mice were injected by the 
In Vivo Therapeutics Core at IUSM with 3.0 x 106 32D cells expressing WT-FLT3, 
N51-FLT3, or N51-FLT3-Y768F and followed for overall survival. 
WT-FLT3-, N51-FLT3-, N51-FLT3-Y768F-
expressing 32D cells
CBC + Peripheral blood 
GFP positivity q3 weeks
Overall Survival
40 C3H/HeJ mice 
(10 WT-FLT3, 15 N51-
FLT3, 15 N51-FLT3-Y768F)
Tail vein injection
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Figure 2.6: Mutation of N51-FLT3 tyrosine (Y) 768 to phenylalanine (F) has no 
effect on Myeloproliferative disease (MPD) in vivo. 
Kaplan-Meier analysis of overall survival for all mice transplanted with 32D cells 
expressing WT-FLT3, N51-FLT3, or N51-FLT3-Y768F, n=10 in the WT-FLT3 group 
and n=15 in the N51-FLT3 and N51-FLT3-Y768F groups respectively; N51-FLT3 and 
N51-FLT3-Y768F groups not significantly different. 
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Pharmacologic inhibition of Shp2 and PI3K reduces FLT3-ITD induced cellular 
hyperproliferation 
Since prior work has implicated a signaling relationship between PI3K, Shp2, 
and WT-FLT3 (Masson, 2009; Zhang, 1999; Zhang, 2000), and our lab has found a 
reduction of p-Akt in N51-FLT3-expressing cells upon pharmacologic inhibition of 
Shp2 (Figure 1.6), we wanted to investigate if there was a cooperative relationship 
between Shp2 and PI3K in FLT3-ITD positive AML. We utilized the Shp2 inhibitor, 
II-B08 (IC50 of 5.5 µM), which has been shown to be critical for the activation of Erk 
(Zhang, 2010), and the PI3K inhibitor, GDC-0941 (IC50 of 3 nM), as PI3K is the 
upstream activator of Akt (Folkes, 2008). The Shp2 inhibitor, II-B08, has been used 
previously and published by us (Zhang, 2010).  The PI3K inhibitor, GDC-0941, is a 
commercially available compound currently in phase 2 clinical trials for non-small 
cell cancer (NSCLC) (Genentech; ClinicalTrials.gov, Identifier-NCT01493843).  Using 
WT-FLT3 and N51-FLT3-expressing 32D cells, we observed that the N51-FLT3-
expressing cells showed a significant reduction of proliferation with II-B08 or GDC-
0941 alone (Figure 2.7A).  We similarly found reduction in the proliferation of 
primary AML samples upon administration of II-B08 or GDC-0941 alone (Figure 
2.7B).  While both II-B08 and GDC-0941 independently demonstrated an effect on 
proliferation, we did not see a strong cooperation of this drug combination in the 
FLT3-ITD-expressing 32D cells or in the primary AML patient samples examined 
(n=4).  However, after examining increased numbers of patient samples (Briana 
Richine, Chan Lab), we did find that the addition of IIB-08 to GDC-0941 significantly 
reduced primary AML cell proliferation compared to treatment with GDC-0941 
alone (data not shown). 
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Figure 2.7: Pharmacologic inhibition of Shp2 and PI3K reduces FLT3-ITD 
induced cellular hyperproliferation 
(A) 3H-thymidine incorporation assay of 32D cells transfected with either WT-
FLT3 or N51-FLT3 in the absence or presence of II-B08 and/or GDC-0941; 
three independent experiments combined with n=3-4 replicates per 
experiment, data normalized to N51-FLT3 proliferation levels, *p<0.0001 for 
no drug (N51-FLT3 or WT-FLT3) vs. II-B08, GDC-0941, or II-B08 + GDC-0941 
for WT or N51 respectively, statistical analysis performed using two-tailed, 
unpaired, student’s t-test.     
(B) 3H-thymidine incorporation of primary AML cells cultured in GM-CSF 1 
ng/mL + FL 50 ng/mL, data normalized to proliferation levels in the absence 
of drug for each sample, n=4 patient samples total, *p<0.0001 for no drug v. 
II-B08, GDC-0941, or II-B08 + GDC-0941, statistical analysis performed using 
two-tailed, unpaired, student’s t-test. 
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CHAPTER THREE 
DISCUSSION 
AML is a lethal disease with a poor overall prognosis, highlighting the need to 
better understand the mechanisms behind disease progression and bring forth 
potential novel therapeutic targets.  Given that FLT3-ITDs are known markers for 
poor prognosis in AML, cultivating a better understanding of their signaling 
pathways may lead to insights that can be applied to the overall disease process.  In 
this study, we investigated the role of Y768 in vitro and in vivo with 32D cells 
expressing N51-FLT3, as well as the effect of pharmacologic inhibition of Shp2 and 
PI3K in vitro. 
Beginning with 32D cells transfected with WT-FLT3, N51-FLT3, or N51-
FLT3-Y768F, we first observed that the Y768 residue is important for cellular 
proliferation as well as Erk activation.  While Masson et al. found that Baf3 cells 
transfected with ITDs containing triple mutation of Y768, Y955, and Y969 had 
reduced cell survival and decreased MAPK and PI3K signaling, our studies further 
define that Y768 alone appears to be a relevant residue for the positive regulation of 
Erk activation in FLT3-ITD positive AML.  Additionally, in our experiments we 
observed no decrease in STAT5 activation upon mutation of the Y768 residue.  One 
possibility for the lack of difference observed in STAT5 phosphorylation between 
N51-FLT3 and N51-FLT3-Y768F might be compensation from other relevant 
tyrosine residues – specifically Y955 and Y969.  Another possibility could be 
contributions from the non-receptor tyrosine kinase, spleen tyrosine kinase (SYK), 
which has been shown to contribute towards STAT5 signaling at other sites along 
the FLT3-ITD receptor (Puissant, 2014; Kanie, 2004). The lack of observed effect on 
Akt activation may be related to alternative pathways in the 32D cell line, given that 
WT-FLT3 and N51-FLT3 were not significantly different.   
Next, we explored the importance of Y768 in myeloproliferative disease 
(MPD) in an in vivo model.  As expected, animals transplanted with N51-FLT3-
expressing cells had decreased survival; however, when comparing N51-FLT3 to 
N51-FLT3-Y768F we saw no improvement in overall survival (Figure 2.6).  The 
decreased survival observed with N51-FLT3-Y768F is inconsistent with the findings 
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of Puissant et al., who found that mice transplanted with constitutively activated 
SYK (SYK-TEL oncogene) and FLT3-ITD-Y768A or FLT3-ITD-Y768/955AA mutant 
construct did not succumb to disease.  Our study did not use the SYK-TEL oncogene 
in animal studies, and these differing results may indicate that oncogenes such as 
SYK may be playing a role in the disease process.  Furthermore, it is worth noting 
that we did not see any effect on STAT5 activation with our N51-FLT3-Y768F-
expressing cells in vitro.  Given that promiscuous activation of STAT5 is one of the 
hallmarks of FLT3-ITD positive AML, it is unlikely that correcting levels of p-Erk 
alone would be sufficient to modify the disease phenotype in vivo.  Other members 
of the lab are actively investigating the role of SYK in N51-FLT3-ITD, which may 
provide insight into the results observed during our current study.   
Our lab has previously established Shp2 as a potential therapeutic target in 
FLT3-ITD positive AML.  Given the mounting evidence of PI3K involvement in FLT3-
ITDs (Masson, 2009; Han, 2015), we further extended our study to include 
inhibition of PI3K in addition to Shp2 in an in vitro model.  We found that 
pharmacologic inhibition of Shp2 with II-B08 led to decreased proliferation in N51-
FLT3-expressing 32D cells as well as primary AML samples, as did administration of 
the PI3K inhibitor GDC-0941 (Figure 2.7).  However, although there was a trend 
towards a cooperative effect observed between administration of both II-B08 and 
GDC-0941, it was not statistically significant (although further data collected in the 
lab has shown cooperativity in primary AML samples).   
Overall, our biochemical and pharmacologic findings confirm the importance 
of Shp2 in FLT3-ITD-induced leukemogenesis and implicate involvement of PI3K.  
We observed consistent findings with the N51-FLT3-Y768F mutant and reduction of 
Erk signaling. We also show that pharmacological inhibition of Shp2 or PI3K can 
decrease cellular hyperproliferation induced by FLT3-ITDs.  Altogether, this study 
supports the involvement of PI3K and Shp2 in AML, and suggests that 
pharmacologic inhibition of Shp2 and/or PI3K may provide a novel approach for 
treatment. 
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